KIT and acute myeloid leukemia: These pathogenic mutations are likely associated with upregulation of KIT expression at the transcript and protein levels, observed in MDS patients, and the overexpression is more noticeable in patients with MDS-EB-1, MDS-EB-2, and secondary AML.